Delisting risk
Q/C Technologies (QCLS)
Developing silicon-photonic processors for AI inference alongside legacy drug candidates.
$1.95
Pre-market+0.04 (+2.09%)
At close$1.91(−8.61%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 7 | |
| Research & development | 3 | 1 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 0 |
| 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | |
| Selling & marketing | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| Other expenses | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Operating income | −5 | −3 | −3 | −2 | −2 | −2 | −2 | −2 | −4 | −2 | −7 |
| 3 | −7 | −6 | 0 | 0 | 1 | 0 | −1 | −2 | 1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −3 | 7 | −2 | 0 | 0 | −1 | 0 | 0 | 2 | −1 | −3 |
| Income before tax | −2 | −10 | −10 | −2 | −2 | −1 | −2 | −3 | −6 | −1 | −7 |
| Net income from continuing operations | −2 | −10 | −10 | −2 | −2 | −1 | −2 | −3 | −6 | −1 | −7 |
| Net income | −2 | −10 | −10 | −2 | −2 | −1 | −2 | −3 | −6 | −1 | −7 |
| EPS, basic | −$293.52 | −$513.84 | −$454.50 | −$110.99 | −$93.23 | −$36.23 | −$17.66 | −$2.50 | −$0.85 | −$0.19 | −$0.81 |
| EPS, diluted | −$293.52 | −$513.84 | −$454.50 | −$110.99 | −$93.23 | −$36.23 | −$17.66 | −$2.50 | −$0.85 | −$0.19 | −$0.81 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 | 8 | 8 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 8 | 8 | 8 |
| EBITDA | 3 | −7 | −2 | −2 | −2 | −1 | −2 | 0 | −6 | −1 | −4 |
| Depreciation & amortization | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| EBIT | −2 | −10 | −2 | −2 | −2 | −1 | −2 | −1 | −6 | −1 | −4 |
